Although the anticoagulant action of
bishydroxycoumarin (Dicumarol) has been
thoroughly studied, clinically as well as in
the laboratory, it is surprising that little
attention has been paid to other possible
pharmacologic effects of this drug. Some
physicians have felt that the drug may have
a possible analgetic effect; others believe
that treatment with bishydroxycoumarin
may increase the speed of resorption of
thrombi. Sougin-Mibashan and Horwitz1
have shown that ethyl biscoumacetate (Tromexan), a related coumarin derivative, increases uric acid excretion. Because of a
special interest in patients with arteriosclerotic heart disease who exhibit hyperuricemia, we have investigated the effect
of bishydroxyxcoumarin on uric acid excretion. The following is a report of the results
of an investigation dealing with the effect
of therapeutic doses of bishydroxycoumarin
on uric acid excretion and uric acid clearance.
Materials and Methods
Eleven patients were studied: five who suffered
from myocardial infarction and three, from
thromboembolic disease